Immunocore reports 2024 KIMMTRAK net sales of $310M; appoints William Pao to board

Immunocore Holdings plc

2024-FY EPS reported -$1.02 revenue$310,202,000

KIMMTRAK Q4 net sales $84.1M; full year $310.0M (+30% YoY); net loss $51.1M ($1.02 EPS) vs $55.3M in 2023.
Ended 2024 with $820.4M cash; repaid $50M Pharmakon loan in Nov 2024.
Advanced PRAME pipeline: Phase 3 PRISM-MEL-301 enrolled first patient; IMC-P115C and IMC-R117C first doses in Phase 1.
Appointed Dr. William Pao (CEO of Revelio Therapeutics) as non-executive director effective Feb 25, 2025.
Expects to present initial HIV data (IMC-M113V) in Q1 2025 and HBV data (IMC-I109V) in H2 2025.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

William Pao

Director

IMCR · Immunocore Holdings plc

Effective: 2025-02-25
Filed: February 26, 2025, 6:59 PM ET

the Board appointed William Pao, M.D., Ph.D. to serve as a Class II director of the Company, effective February 25, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William Pao was appointed as Director at Immunocore Holdings plc.

Action: appointed
Role: Director

Exact text from the filing

the Board appointed William Pao, M.D., Ph.D. to serve as a Class II director of the Company, effective February 25, 2025.

View on SEC.gov

Immunocore Holdings plc filing history →

Source: SEC EDGAR

accession 0001140361-25-005988

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.